載入...
Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for ovarian c...
Na minha lista:
| 發表在: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7226328/ https://ncbi.nlm.nih.gov/pubmed/32260415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040880 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|